NCT01848340 - An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

HIV-associated Lipodystrophy Syndrome

Interventions

DRUG

GSK1265744B (sodium salt) containing 14C-GSK1265744B

A white to slightly colored nonsterile crystalline powder for oral solution

DRUG

150 mg GSK1265744B

This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet

DRUG

Placebo

Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet

Trial Locations (1)

66211

GSK Investigational Site, Overland Park